Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

talazoparib × Other solid neoplasm × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 13 Genitourinary 12 Gynecologic 6 Tumor-Agnostic 3 Gastrointestinal 3 CNS 3 Thoracic 2 Sarcoma 2 Other hematologic neoplasm 2 Plasma cell 1 Other solid neoplasm 1 Lymphoid 1 Endocrine 1

Conditions

Advanced Solid Tumor 1

Interventions

pembrolizumab 68 Injections 53 Carboplatin 33 Nivolumab 30 Cisplatin 28 Pemetrexed 25 Bevacizumab 23 tislelizumab 21 Paclitaxel 21 Interviews as Topic 21 Cyclophosphamide 20 Specimen Handling 19 atezolizumab 18 Docetaxel 17 Standard of Care 16 Practice Guidelines as Topic 16 Fluorouracil 15 Ipilimumab 14 Educational Status 14 Oxaliplatin 13 Cetuximab 13 fludarabine 12 Leucovorin 12 toripalimab 11 Methods 11 Early Intervention, Educational 11 Gemcitabine 10 Drug Therapy 10 spartalizumab 9 olaparib 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04497116 2025-10-21

TRESR

Repare Therapeutics

Phase 1/2 Completed

276 enrolled 33 charts

Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡